Korsana Biosciences Inc

1. 1

   Domestication Proposal

   ManagementBoard: FOR

   Approve the redomestication of Korsana Biosciences, Inc. from a Massachusetts corporation to a Cayman Islands exempted company by domestication under Section 9.20 of the Massachusetts Business Corporation Act and adopt the Board’s Redomestication Resolutions.

   More detail

   Proposal No. 1 asks shareholders to approve the Massachusetts-law domestication step of the Company’s proposed move to the Cayman Islands. Approval would authorize the Plan of Domestication and the Board’s Redomestication Resolutions. The transaction is designed to preserve the Company as the same legal entity while changing the jurisdiction governing its internal corporate affairs. Existing common shares would automatically convert into one Cayman ordinary share per share, and preferred shares, options and warrants would receive corresponding treatment. Management states that the move could reduce opportunistic shareholder demands and litigation, particularly because Cayman law generally provides narrower inspection and direct-action rights. The Board also believes Cayman law may provide greater exculpation and indemnification flexibility for directors and officers, helping attract and retain management. The Board further cites greater flexibility and predictability in certain corporate transactions, including because Massachusetts business-combination protections would no longer apply. The proposal follows a failed August 26, 2026 vote in which approximately 61.8% of votes cast supported redomestication but turnout was insufficient to meet the Massachusetts requirement of two-thirds of all shares entitled to vote. Approval of this proposal alone is insufficient because Proposal No. 2 must also pass, and the Board unanimously recommends a vote FOR.

2. 2

   Continuation and Cayman Articles Proposal

   ManagementBoard: FOR

   Approve the continuation of the Company from Massachusetts to the Cayman Islands under Cayman law, approve the Redomestication Resolutions, and adopt the Cayman Islands memorandum and articles of association as a special resolution.

   More detail

   Proposal No. 2 asks shareholders to approve the Cayman-law continuation step and adopt the Company’s proposed Cayman memorandum and articles of association. It is presented as a special resolution, requiring at least two-thirds of votes properly cast by shareholders attending or represented by proxy. The proposal works together with Proposal No. 1; neither domestication nor continuation will occur unless both proposals are approved. The Cayman Articles would replace the Massachusetts Articles and Bylaws and would introduce a classified three-class board with staggered three-year terms. They would also impose Cayman exclusive-forum provisions, advance-notice requirements, restrictions on director removal, and board authority over preferred-share issuances and certain governance matters. Management argues that Cayman law may reduce direct shareholder litigation and inspection demands, broaden protections for directors and officers, and provide more flexibility in corporate transactions. The Cayman Series B preferred shares would retain significant protective rights, including consent rights over specified transactions and the right to elect four directors while the applicable ownership threshold remains satisfied. The Company would remain the same legal entity, retain its business, management, Nasdaq listing and SEC reporting obligations, and continue to be treated as a U.S. corporation for federal tax purposes. The Board unanimously recommends a vote FOR, while acknowledging that shareholder rights would differ materially from those under Massachusetts law.

3. 3

   Adjournment Proposal

   ManagementBoard: FOR

   Approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes to approve Proposals 1 and 2.

   More detail

   Proposal No. 3 asks shareholders to authorize one or more adjournments of the Special Meeting if additional proxies are needed to approve Proposals No. 1 and No. 2. The principal purpose is to give the Company more time to solicit votes supporting the Redomestication. An approved adjournment could be used even where current proxies indicate that one of the Redomestication proposals would otherwise fail. The Company may seek votes from shareholders who have not voted or who previously submitted opposing proxies. The chair may also have authority under the bylaws and applicable law to adjourn the meeting, and properly submitted proxies generally remain valid at an adjourned meeting. Approval requires affirmative votes to exceed opposing votes, with abstentions and broker non-votes having no effect on the outcome. The Adjournment Proposal is not a condition to the Redomestication, and its approval is not conditioned on approval of Proposals No. 1 or No. 2. If it fails and the Redomestication proposals lack sufficient support, the Company may be unable to adjourn for additional solicitation and the Redomestication would not occur. The Board unanimously recommends a vote FOR because it believes additional solicitation could help obtain the votes required for the Company’s proposed change of domicile.

Upcoming shareholder meetings at Korsana Biosciences Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Korsana Biosciences Inc 2026 special meeting?

Korsana Biosciences Inc (KRSA) holds its 2026 special shareholder meeting on Friday, November 13, 2026.

What is the record date for the Korsana Biosciences Inc 2026 meeting?

The record date for the Korsana Biosciences Inc 2026 meeting is Wednesday, October 7, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Korsana Biosciences Inc's 2026 meeting?

The board is presenting 8 director nominees at the Korsana Biosciences Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Korsana Biosciences Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Korsana Biosciences Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.